Compare · ONTO vs TMO
ONTO vs TMO
Side-by-side comparison of Onto Innovation Inc. (ONTO) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ONTO and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $174.30B, about 12.0x ONTO ($14.57B).
- TMO has been more active in the news (10 items in the past 4 weeks vs 8 for ONTO).
- TMO has more recent analyst coverage (25 ratings vs 18 for ONTO).
- Company
- Onto Innovation Inc.
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $14.57B
- $174.30B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 8
- 10
- Recent ratings
- 18
- 25
Onto Innovation Inc.
Onto Innovation Inc. engages in the design, development, manufacture, and support of process control tools that performs macro defect inspection and metrology, lithography systems, and process control analytical software worldwide. It offers process and yield management solutions, and device packaging and test facilities through standalone systems for macro-defect inspection, packaging lithography, probe card test and analysis, and transparent and opaque thin film measurements; and process control software portfolio that includes solutions for standalone tools, groups of tools, or factory-wide suites. The company also provides spare parts and software licensing services. Its products are used by semiconductor wafer and advanced packaging device manufacturers; silicon wafer; light emitting diode; vertical-cavity surface-emitting laser; micro-electromechanical system; CMOS image sensor; power device; RF filter; data storage; and various industrial and scientific applications. The company was formerly known as Rudolph Technologies, Inc. Onto Innovation Inc. was founded in 1940 and is headquartered in Wilmington, Massachusetts.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest ONTO
- Onto Innovation Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Onto Innovation Announces Strategic Partnership With Leading X-Ray Provider Rigaku To Advance Next-Generation Process Control Solutions
- Onto Innovation upgraded by Stifel with a new price target
- Onto Innovation to Report First Quarter 2026 Financial Results on May 5, 2026
- Onto Innovation Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Onto Innovation's Dragonfly® G5 System Qualified for Applications in 2.5D AI Packaging
- SEC Form DEFA14A filed by Onto Innovation Inc.
- SEC Form DEF 14A filed by Onto Innovation Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Onto Innovation Inc.
- Onto Innovation Launches Dragonfly® G5 Inspection System
Latest TMO
- SEC Form 10-Q filed by Thermo Fisher Scientific Inc
- President & COO Pettiti Gianluca sold $185,064 worth of shares (400 units at $462.66) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 25,051 units (SEC Form 4)
- Thermo Fisher Scientific to Host Investor Day
- Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports First Quarter 2026 Results
- AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
- Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
- SEC Form DEFA14A filed by Thermo Fisher Scientific Inc
- SEC Form DEF 14A filed by Thermo Fisher Scientific Inc